The Neuroendocrine Tumors drugs in development market research report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neuroendocrine Tumors. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued products.

GlobalData tracks 111 drugs in development for Neuroendocrine Tumors by 98 companies/universities/institutes. The top development phase for Neuroendocrine Tumors is phase ii with 54 drugs in that stage. The Neuroendocrine Tumors pipeline has 106 drugs in development by companies and five by universities/ institutes. Some of the companies in the Neuroendocrine Tumors pipeline products market are: Ipsen, Merck and Eli Lilly and Co.

The key targets in the Neuroendocrine Tumors pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Somatostatin Receptor Type 2 (SRIF1 or SSTR2), and Cells Expressing Somatostatin Receptor Type 2 (SRIF1 or SSTR2).

The key mechanisms of action in the Neuroendocrine Tumors pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with ten drugs in Phase III. The Neuroendocrine Tumors pipeline products include 18 routes of administration with the top ROA being Intravenous and 15 key molecule types in the Neuroendocrine Tumors pipeline products market including Small Molecule, and Monoclonal Antibody.

Neuroendocrine Tumors overview

Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptoms include hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety, and gastric ulcer disease. Treatments include surgery, radiation therapy, and chemotherapy.

For a complete picture of Neuroendocrine Tumors’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.